Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation Therapy
Phase 3
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Registration Number
- CTRI/2024/04/066217
- Lead Sponsor
- Amrita School of Pharmacy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
(a) patients who are on the Memantine arm of CTRI/2022/01/039599 Trial
(b) Patients who are willing to participate in the study, and provide informed consent
Exclusion Criteria
(a) Patients who are on the placebo Arm of CTRI/2022/01/039599 Trial
(b) Patients who are not willing to participate in the study, and provide informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the therapeutic drug concentration in Indian patients with different dosage scheduleTimepoint: 1 month
- Secondary Outcome Measures
Name Time Method 2.To correlate the Toxicity profile with serum memantine concentration <br/ ><br>Timepoint: 1 month;To determine the correlation serum memantine concentration with cognitive function preservation <br/ ><br>Timepoint: 1 month